 Eduardo Davila
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 5 | 2023 | 735 | 1.930 |
Why?
| | Antigens, Neoplasm | 3 | 2017 | 308 | 1.780 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 3 | 2020 | 28 | 1.560 |
Why?
| | T-Lymphocytes | 5 | 2023 | 1911 | 1.220 |
Why?
| | Neoplasms | 6 | 2021 | 2435 | 1.120 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2021 | 98 | 1.070 |
Why?
| | Melanoma, Experimental | 3 | 2015 | 105 | 1.030 |
Why?
| | Chromones | 2 | 2019 | 46 | 0.970 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2021 | 832 | 0.960 |
Why?
| | DNA-Activated Protein Kinase | | | 16 | NaN |
Why?
| | Morpholines | 2 | 2019 | 126 | 0.910 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 870 | 0.860 |
Why?
| | Immunotherapy, Adoptive | 5 | 2021 | 286 | 0.820 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2021 | 699 | 0.790 |
Why?
| | Cancer Vaccines | 1 | 2019 | 164 | 0.770 |
Why?
| | Cell Engineering | 1 | 2021 | 8 | 0.750 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 141 | 0.750 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 21 | 0.710 |
Why?
| | Toll-Like Receptor 2 | 3 | 2010 | 124 | 0.700 |
Why?
| | Immunotherapy | 3 | 2021 | 581 | 0.680 |
Why?
| | Caspase 3 | 1 | 2020 | 242 | 0.640 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 592 | 0.640 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1570 | 0.640 |
Why?
| | CD8 Antigens | 1 | 2017 | 75 | 0.630 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2023 | 593 | 0.630 |
Why?
| | Calcium-Binding Proteins | 1 | 2020 | 213 | 0.620 |
Why?
| | Dendritic Cells | 2 | 2019 | 479 | 0.620 |
Why?
| | Mice, Inbred NOD | 6 | 2021 | 579 | 0.600 |
Why?
| | Phenylurea Compounds | 1 | 2017 | 89 | 0.580 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 420 | 0.560 |
Why?
| | Apoptosis | 2 | 2020 | 2485 | 0.550 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1315 | 0.550 |
Why?
| | Mice, SCID | 5 | 2021 | 343 | 0.540 |
Why?
| | Mice | 13 | 2021 | 16585 | 0.530 |
Why?
| | Genetic Variation | 1 | 2021 | 936 | 0.510 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2021 | 797 | 0.490 |
Why?
| | Toll-Like Receptors | 3 | 2012 | 182 | 0.490 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2008 | 166 | 0.490 |
Why?
| | Flagellin | 1 | 2015 | 17 | 0.480 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 3106 | 0.480 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 640 | 0.470 |
Why?
| | Animals | 16 | 2021 | 34733 | 0.460 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 2039 | 0.450 |
Why?
| | Pyridines | 1 | 2017 | 472 | 0.440 |
Why?
| | Benzimidazoles | 1 | 2015 | 158 | 0.440 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 429 | 0.410 |
Why?
| | Lymphocytes, Tumor-Infiltrating | | | 203 | NaN |
Why?
| | T-Lymphocyte Subsets | 3 | 2021 | 413 | 0.410 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1360 | 0.400 |
Why?
| | Cell Proliferation | 5 | 2020 | 2340 | 0.390 |
Why?
| | Lymphocyte Activation | 5 | 2019 | 1095 | 0.360 |
Why?
| | Signal Transduction | 3 | 2021 | 4863 | 0.360 |
Why?
| | Adoptive Transfer | 2 | 2008 | 221 | 0.300 |
Why?
| | Thymoma | 1 | 2010 | 31 | 0.300 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 35 | 0.260 |
Why?
| | Humans | 17 | 2023 | 129706 | 0.260 |
Why?
| | Mice, Knockout | 2 | 2021 | 2778 | 0.250 |
Why?
| | Mice, Inbred C57BL | 4 | 2017 | 5279 | 0.250 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 466 | 0.250 |
Why?
| | Antigens, CD | 2 | 2021 | 479 | 0.250 |
Why?
| | CD47 Antigen | | | 23 | NaN |
Why?
| | Diphtheria Toxin | | | 56 | NaN |
Why?
| | Immunotoxins | | | 45 | NaN |
Why?
| | Lymphoma, T-Cell, Peripheral | | | 16 | NaN |
Why?
| | Immunodominant Epitopes | | | 28 | NaN |
Why?
| | Gamma Rays | 1 | 2023 | 52 | 0.210 |
Why?
| | Antigens, Differentiation | | | 82 | NaN |
Why?
| | Intramolecular Oxidoreductases | | | 67 | NaN |
Why?
| | Oligodeoxyribonucleotides | | | 139 | NaN |
Why?
| | CpG Islands | | | 151 | NaN |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 73 | 0.210 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2075 | 0.200 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 62 | 0.200 |
Why?
| | Cell Communication | 2 | 2019 | 292 | 0.200 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2005 | 380 | 0.200 |
Why?
| | Immunoconjugates | | | 101 | NaN |
Why?
| | Adjuvants, Immunologic | | | 224 | NaN |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 108 | 0.190 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2017 | 214 | 0.190 |
Why?
| | Antigen Presentation | 2 | 2017 | 205 | 0.190 |
Why?
| | CD3 Complex | 1 | 2021 | 100 | 0.180 |
Why?
| | Semaphorins | 1 | 2021 | 25 | 0.180 |
Why?
| | Skin Neoplasms | 1 | 2008 | 829 | 0.180 |
Why?
| | Heterografts | 1 | 2021 | 129 | 0.180 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4016 | 0.180 |
Why?
| | Genetic Engineering | 1 | 2021 | 89 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 138 | 0.170 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 539 | 0.170 |
Why?
| | Multiprotein Complexes | 1 | 2021 | 147 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 177 | 0.170 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 164 | 0.160 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 339 | 0.160 |
Why?
| | Cytokines | 3 | 2012 | 2008 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2021 | 576 | 0.150 |
Why?
| | Leukemia | 1 | 2021 | 228 | 0.150 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 929 | 0.150 |
Why?
| | HLA-A2 Antigen | 2 | 2010 | 48 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-pim-1 | | | 2 | NaN |
Why?
| | Jurkat Cells | 1 | 2015 | 136 | 0.140 |
Why?
| | CD55 Antigens | 1 | 2017 | 26 | 0.140 |
Why?
| | Gene Duplication | | | 67 | NaN |
Why?
| | 5'-Nucleotidase | 1 | 2017 | 37 | 0.140 |
Why?
| | Genes, MHC Class I | 1 | 2017 | 33 | 0.140 |
Why?
| | fms-Like Tyrosine Kinase 3 | | | 47 | NaN |
Why?
| | Cell Survival | 2 | 2015 | 1083 | 0.140 |
Why?
| | DNA-Binding Proteins | | | 1423 | NaN |
Why?
| | Receptors, Virus | 1 | 2017 | 81 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2021 | 730 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 596 | 0.140 |
Why?
| | Immunomodulation | 1 | 2017 | 90 | 0.130 |
Why?
| | Protein Binding | 2 | 2021 | 2088 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1106 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 531 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2017 | 174 | 0.120 |
Why?
| | Toll-Like Receptor 5 | 1 | 2015 | 14 | 0.120 |
Why?
| | TNF Receptor-Associated Factor 6 | 1 | 2015 | 4 | 0.120 |
Why?
| | Immune Tolerance | 1 | 2017 | 348 | 0.120 |
Why?
| | Nitrophenols | 1 | 2015 | 33 | 0.120 |
Why?
| | MCF-7 Cells | 1 | 2015 | 109 | 0.120 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 55 | 0.120 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 254 | 0.120 |
Why?
| | Vaccination | | | 1362 | NaN |
Why?
| | Vincristine | 1 | 2015 | 109 | 0.120 |
Why?
| | Protein Stability | 1 | 2015 | 160 | 0.110 |
Why?
| | Drug Synergism | 1 | 2015 | 354 | 0.110 |
Why?
| | Interferon-gamma | 1 | 2010 | 765 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 196 | 0.110 |
Why?
| | Flow Cytometry | 1 | 2017 | 1151 | 0.110 |
Why?
| | Antifreeze Proteins | | | 1 | NaN |
Why?
| | Gadus morhua | | | 1 | NaN |
Why?
| | Histocompatibility Antigens Class II | 1 | 2015 | 360 | 0.110 |
Why?
| | Fish Proteins | | | 10 | NaN |
Why?
| | Galectin 3 | | | 19 | NaN |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 20 | 0.100 |
Why?
| | Receptors, Antigen | 1 | 2012 | 14 | 0.100 |
Why?
| | Cell Growth Processes | 1 | 2012 | 52 | 0.100 |
Why?
| | Female | 5 | 2021 | 68562 | 0.100 |
Why?
| | Piperazines | 1 | 2015 | 327 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2015 | 673 | 0.100 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1306 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2011 | 5 | 0.090 |
Why?
| | Sulfonamides | 1 | 2015 | 494 | 0.090 |
Why?
| | Perforin | 1 | 2010 | 19 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2012 | 812 | 0.090 |
Why?
| | Male | 5 | 2021 | 63544 | 0.090 |
Why?
| | Cell Movement | 1 | 2015 | 934 | 0.090 |
Why?
| | Granzymes | 1 | 2010 | 47 | 0.090 |
Why?
| | Mutation | 1 | 2021 | 3674 | 0.080 |
Why?
| | T-Box Domain Proteins | 1 | 2010 | 96 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 3893 | 0.080 |
Why?
| | Cells, Cultured | 1 | 2017 | 4058 | 0.080 |
Why?
| | Receptors, Immunologic | 1 | 2011 | 214 | 0.080 |
Why?
| | Protein Kinase C | 1 | 2010 | 259 | 0.080 |
Why?
| | Graft vs Host Disease | 1 | 2011 | 238 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 359 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1687 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2005 | 1049 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 380 | 0.070 |
Why?
| | Adenocarcinoma | | | 895 | NaN |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1696 | 0.060 |
Why?
| | B7-2 Antigen | 1 | 2005 | 26 | 0.060 |
Why?
| | Prostatic Neoplasms | | | 995 | NaN |
Why?
| | CD28 Antigens | 1 | 2005 | 49 | 0.060 |
Why?
| | CD56 Antigen | 1 | 2005 | 37 | 0.060 |
Why?
| | Antigen-Presenting Cells | 1 | 2005 | 155 | 0.060 |
Why?
| | Synovial Membrane | 1 | 2005 | 85 | 0.060 |
Why?
| | Clone Cells | 1 | 2005 | 257 | 0.060 |
Why?
| | Immunophenotyping | 1 | 2005 | 311 | 0.060 |
Why?
| | Thymus Neoplasms | | | 22 | NaN |
Why?
| | Abatacept | | | 47 | NaN |
Why?
| | Vaccines, Subunit | | | 47 | NaN |
Why?
| | CTLA-4 Antigen | | | 88 | NaN |
Why?
| | CD4 Antigens | | | 137 | NaN |
Why?
| | Down-Regulation | 1 | 2005 | 637 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 125 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 29 | 0.050 |
Why?
| | Graft vs Tumor Effect | 1 | 2021 | 8 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2522 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 68 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 85 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 946 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 404 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2768 | 0.040 |
Why?
| | Amino Acid Sequence | | | 2051 | NaN |
Why?
| | Molecular Sequence Data | | | 2848 | NaN |
Why?
| | Benzothiazoles | | | 32 | NaN |
Why?
| | Membrane Potential, Mitochondrial | | | 65 | NaN |
Why?
| | Proteolysis | | | 162 | NaN |
Why?
| | Protein Processing, Post-Translational | | | 448 | NaN |
Why?
| | Reactive Oxygen Species | | | 579 | NaN |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | | | 8 | NaN |
Why?
| | Proteome | | | 426 | NaN |
Why?
| | Phenotype | 1 | 2021 | 3063 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | | | 95 | NaN |
Why?
| | Neovascularization, Pathologic | | | 293 | NaN |
Why?
| | Neoplasm Metastasis | | | 610 | NaN |
Why?
| | Aged | 1 | 2021 | 22113 | 0.010 |
Why?
| | Middle Aged | 1 | 2021 | 31103 | 0.010 |
Why?
|
|
Davila's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|